Literature DB >> 12713589

Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma.

Katy Argentati1, Francesca Re, Stefano Serresi, Maria G Tucci, Beatrice Bartozzi, Giovanni Bernardini, Mauro Provinciali.   

Abstract

We studied the peripheral representation, in vitro expansion, cytokine production, and cytotoxicity of gamma delta T lymphocytes from 23 patients with cutaneous primary melanoma and 28 healthy subjects. We demonstrated that the absolute number and the percentage of circulating gamma delta + T cells were significantly reduced in melanoma patients in comparison with healthy subjects. The decrease was due to a reduction of V delta 2 T cells, whereas the number of V delta 1 T cells was not affected. As a consequence, the V delta 2/V delta 1 ratio was inverted in melanoma patients. A lower percentage of gamma delta + T cells producing tumor necrosis factor-alpha or interferon-gamma was found in melanoma patients. After a 10 d in vitro culture, both the percentage and the expansion index of gamma delta T cells, and in particular of V delta 2 subset, were significantly reduced in melanoma patients in comparison with healthy subjects. The cytotoxicity of sorted gamma delta T cells against tumor cell lines and the percentage of gamma delta T cells producing perforins were preserved in melanoma patients. The numerical and functional impairment of gamma delta T cells could contribute to the inadequate immune response found in melanoma patients and offers the potentiality for the planning of new approaches of immune therapy of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713589     DOI: 10.1046/j.1523-1747.2003.12141.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  24 in total

1.  Histamine modulates γδ-T lymphocyte migration and cytotoxicity, via Gi and Gs protein-coupled signalling pathways.

Authors:  K Truta-Feles; M Lagadari; K Lehmann; L Berod; S Cubillos; S Piehler; Y Herouy; D Barz; T Kamradt; Aa Maghazachi; J Norgauer
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis.

Authors:  Ute Laggner; Paola Di Meglio; Gayathri K Perera; Christian Hundhausen; Katie E Lacy; Niwa Ali; Catherine H Smith; Adrian C Hayday; Brian J Nickoloff; Frank O Nestle
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

Review 3.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

4.  Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Authors:  Kilian Wistuba-Hamprecht; Alexander Martens; Karin Haehnel; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Anis Larbi; Bastian Schilling; Dirk Schadendorf; Jedd D Wolchok; Christian U Blank; Graham Pawelec; Claus Garbe; Benjamin Weide
Journal:  Eur J Cancer       Date:  2016-07-09       Impact factor: 9.162

5.  A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

Authors:  Renée C G de Bruin; John P Veluchamy; Sinéad M Lougheed; Famke L Schneiders; Silvia Lopez-Lastra; Roeland Lameris; Anita G Stam; Zsolt Sebestyen; Jürgen Kuball; Carla F M Molthoff; Erik Hooijberg; Rob C Roovers; James P Di Santo; Paul M P van Bergen En Henegouwen; Henk M W Verheul; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Oncoimmunology       Date:  2017-10-20       Impact factor: 8.110

6.  The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome.

Authors:  Pauline Girard; Julie Charles; Camille Cluzel; Emmanuelle Degeorges; Olivier Manches; Joel Plumas; Florence De Fraipont; Marie-Therese Leccia; Stephane Mouret; Laurence Chaperot; Caroline Aspord
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

7.  Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.

Authors:  Nichole L Bryant; Catalina Suarez-Cuervo; G Yancey Gillespie; James M Markert; L Burt Nabors; Sreelatha Meleth; Richard D Lopez; Lawrence S Lamb
Journal:  Neuro Oncol       Date:  2009-02-11       Impact factor: 12.300

Review 8.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

9.  Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation.

Authors:  Lionel Couzi; Yann Levaillant; Abdellah Jamai; Vincent Pitard; Regis Lassalle; Karin Martin; Isabelle Garrigue; Omar Hawchar; François Siberchicot; Nicholas Moore; Jean-François Moreau; Julie Dechanet-Merville; Pierre Merville
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

Review 10.  Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Authors:  Gabrielle M Siegers; Lawrence S Lamb
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.